Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ayahuasca/Adolescents

Ayahuasca for Adolescents

14 papers and 0 clinical trials exploring ayahuasca as a treatment for adolescents.

Compoundclassic psychedelic

Ayahuasca

Ayahuasca is a botanical decoction combining DMT with MAO-inhibiting harmala alkaloids, producing intense psychedelic effects lasting 3-6 hours. Clinical trials show rapid, large antidepressant effects from a single dose, with a favourable safety profile in controlled settings.

Full Ayahuasca profile
Indication1 in 7 adolescents lives with a mental disorder

Adolescents

Adolescents are a developing-brain, vulnerable population that the modern psychedelic field has mostly studied from the outside: almost all psychedelic trials enrol adults, not minors. The one mature clinical thread in under-18s is ketamine and esketamine for depression and acute suicidality, where benefits are real but modest and often matched by active-placebo arms. For classic psychedelics like psilocybin, LSD and MDMA there is essentially no controlled evidence in adolescents, and the developing brain raises safety questions that adult data cannot answer.

Full Adolescents profile

Academic Research

14 papers
Paywallindividual

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression

This open-label fixed-order dose-escalation trial (n=14) evaluated inhaled DMT (15mg & 60mg) for treatment-resistant depression (TRD) for the first time. Results showed rapid and sustained antidepressant effects with a 21-point reduction on the Montgomery-Asberg Depression Rating Scale by day 7 (p<0.001), an 86% response rate, and a 57% remission rate lasting up to 3 months, with significant decreases in suicidal ideation (SI).

Published
April 22, 2025
Journal
Neuropsychopharmacology
Authors
Falchi-Carvalho, M., Palhano-Fontes, F., Wießner, I., Barros, H., Bolcont, R., Laborde, S., Silva, S. R. B., Montanini, D., Barbosa, D. C., Teixeira, E., Florence-Vilela, R., Almeida, R., Macedo, R. K. A., Arichelle, F., Pantrigo, E. J., Costa-Macedo, J. V., da Cruz Nunes, J. A., Araújo, D. B., de Araujo Costa Neto, L. A., Nunes Ferreira, L. F., Dantas Correa, L., da Costa Bezerra, R. B., Arcoverde, E., Galvão-Coelho, N. L.
Open Accessindividual

Childhood trauma, challenging experiences, and posttraumatic growth in ayahuasca use

In an online survey of 231 ayahuasca users, self‑reported childhood trauma was not associated with greater challenging experiences during acute ayahuasca effects nor with differences in posttraumatic growth, and acute challenging experiences were not linked to increased posttraumatic growth; this suggests childhood trauma may not predict poorer response to ayahuasca as it does for some other interventions.

Published
March 20, 2024
Journal
Drug Science Policy and Law
Authors
Cassidy, K., Healy, C. J., Henje, E., D'andrea, W.
Open Accessmeta

Drug-drug interactions involving classic psychedelics: A systematic review

This systematic review of 52 human studies summarises drug–drug interactions between classic psychedelics (LSD, psilocybin, mescaline, DMT, 5‑MeO‑DMT) and various psychotropic and recreational drugs, finding heterogeneous outcomes — attenuated, potentiated or unchanged effects — with few serious adverse events reported beyond isolated case reports. The paper provides a comprehensive synthesis of clinical evidence and discusses potential molecular mechanisms underlying these interactions.

Published
November 20, 2023
Journal
Journal of Psychopharmacology
Authors
Halman, A., Kong, G., Sarris, J., Perkins, D.
Open Accessindividual

Ayahuasca in the treatment of bipolar disorder with psychotic features-A retrospective case study

This retrospective case study describes a woman with bipolar disorder and psychotic features whose suicidality, dissociation and social isolation markedly improved and were sustained after multiple ayahuasca ceremonies, with corroboration of childhood abuse and ongoing symptom reduction over several years. The report suggests potential therapeutic benefits of ayahuasca for severe traumatisation and bipolar symptoms and situates the case within a brief review of low‑dose ayahuasca and LSD treatment literature.

Published
March 10, 2023
Journal
Psyarxiv
Authors
Turkia, M.
Paywallindividual

Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences

In a survey of 2,516 participants, greater lifetime naturalistic use of psychedelics predicted higher trait positive and lower negative emotional reactivity, increased reflective/internal self-awareness, and reduced rumination and public self-consciousness. These associations were largely mediated by the intensity of past ego-dissolution and mystical experiences, suggesting such acute experiences underpin long-lasting adaptive changes.

Published
April 27, 2022
Journal
Journal of Psychopharmacology
Authors
Orłowski, P., Ruban, A., Szczypiński, J., Hobot, J., Bielecki, M., Bola, M.
Open Accessindividual

Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil

This survey study (n=411) assessed the factors that predict smoking cessation in people who reported quitting or reducing smoking following ayahuasca consumption. Mystical experience and frequency of ayahuasca intake were protective factors, while positive mood (measured by the MEQ30) during the ayahuasca experience was a risk factor. Qualitative analysis revealed eight themes related to the process of smoking cessation/reduction.

Published
February 18, 2022
Journal
Psychopharmacology
Authors
Maia, L. O., Massarentti, C. M., Tófoli, L.F.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ayahuasca and Adolescents yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ayahuasca papers Search all Adolescents trials Full Ayahuasca profile Full Adolescents profile